[Inhalation and peroral mucolytic therapy in mucoviscidosis in children].
The paper summarizes the results of clinical studies of 98 children with mucoviscidosis whose age was 7 to 18 years. There is research evidence for possibility and expediency of using new classes of mucolytic agents in the therapy of mucoviscidosis in children. Analysis of the rheological properties of sputum showed the advantage of inhalation route of mucolytics over their oral administration. There is evidence for the advantage of mucosolvan over carbocysteine and unithiol via all routes of administration, the optimal methods of administration and differentiated indications have been developed.
Uglitskikh
A K
AK
Khan
M A
MA
Sharapov
S V
SV
Kapranov
N I
NI
Plisko
L F
LF
D000280:Administration, Inhalation; D000284:Administration, Oral; D000293:Adolescent; D000551:Ambroxol / Q000008:administration & dosage* / Q000494:pharmacology; D002233:Carbocysteine / Q000008:administration & dosage* / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D004341:Drug Evaluation; D005100:Expectorants / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D007223:Infant; D012119:Respiration / Q000187:drug effects; D013183:Sputum / Q000187:drug effects; D014494:Unithiol / Q000008:administration & dosage* / Q000494:pharmacology
D005100:Expectorants; D000551:Ambroxol; D014494:Unithiol; D002233:Carbocysteine